Serum (1→3)-β‑D‑Glucan Testing: Indications, Interpretation, and Management

When to Order the Test

• Serial serum (1→3)-β‑D‑glucan testing twice weekly is recommended for patients with hematologic malignancies, allogeneic hematopoietic stem cell transplant recipients, or those with prolonged profound neutropenia who are at high risk for invasive fungal infection. 1
• Specific high‑risk scenarios include:
  
  • Acute myeloid leukemia or myelodysplastic syndrome undergoing intensive chemotherapy. 1
  • Allogeneic stem cell transplant recipients during neutropenic periods. 1
  • Persistently febrile neutropenic patients despite broad‑spectrum antibiotics. 1
• In neonates with suspected invasive candidiasis, β‑D‑glucan testing is advised when blood cultures are negative or delayed. [2][3]
• Testing should not be performed in low‑risk patients without significant immunosuppression. 1

Diagnostic Cutoff Values and Test Performance

• The FDA‑cleared Fungitell assay defines a positive result as > 80 pg/mL; some studies have evaluated a lower cutoff of ≥ 60 pg/mL. 3

Interpretation of Positive Results

• A positive β‑D‑glucan (>80 pg/mL) indicates a probable invasive fungal infection but is not species‑specific; it cannot differentiate among Candida, Aspergillus, Fusarium, or Pneumocystis jirovecii. 4
• Immediate actions after a positive result: obtain blood and site‑specific cultures, and perform chest CT imaging if pulmonary symptoms are present. 4
• Sensitivity for detecting specific organisms: Candida ≈ 81 %, Aspergillus ≈ 80 %, with additional detection of Fusarium and P. jirovecii. 4
• The assay is negative for organisms lacking β‑D‑glucan such as Cryptococcus neoformans, Mucor, and Rhizopus (zygomycetes). 4

Interpretation of Negative Results

• A negative β‑D‑glucan (<80 pg/mL) has a high negative predictive value (≈ 73‑75 %) and can help rule out invasive fungal infection when clinical context is appropriate. (Evidence from the same studies that defined assay performance.)
• However, a negative result does not exclude invasive aspergillosis in patients already receiving mold‑active antifungal therapy. 4
• Serial negative results in high‑risk patients support withholding empiric antifungal therapy. 1

Common False‑Positive Causes (Must Be Excluded Before Treatment)

• Hemodialysis using cellulose membranes. 1
• Administration of blood products such as albumin or intravenous immunoglobulin. 1
• Certain antibiotics, including β‑lactam/β‑lactamase inhibitor combinations (e.g., piperacillin‑tazobactam, amoxicillin‑clavulanate), some cephalosporins, carbapenems, and ampicillin‑sulbactam. [4][1]
• Exposure of surgical sites or wound dressings to gauze or other glucan‑contaminated materials. [4][1]

Guiding Antifungal Therapy

Initiation Criteria

• Antifungal therapy should be started when a positive β‑D‑glucan result is accompanied by clinical signs of infection (e.g., fever, hemodynamic instability, organ dysfunction). 4

Targeted Therapy for Specific Pathogens

• Suspected invasive candidiasis:
  
  • In non‑neutropenic patients, an echinocandin (caspofungin, micafungin, anidulafungin) is first‑line.
  • In neutropenic patients, either an echinocandin or liposomal amphotericin B may be used.
• Suspected invasive aspergillosis (with concurrent positive galactomannan):
  
  • Voriconazole or isavuconazole are first‑line agents; liposomal amphotericin B is an alternative. 4

Special Considerations

• In neonates, blood culture sensitivity ranges from 21 % to 71 %; therefore, a negative culture does not exclude invasive candidiasis. 2
• Antifungal prophylaxis or ongoing treatment can reduce β‑D‑glucan test sensitivity; results must be interpreted cautiously in patients already receiving antifungals. 4

Treatment Approach for Positive Fungitell Result

Understanding Fungitell Testing

• Fungitell is an FDA-approved serum β-D-glucan assay that detects (1,3)-β-D-glucan, a cell wall component found in many fungi including Candida, Aspergillus, Pneumocystis jirovecii, and others 5
• The test has a pooled sensitivity of 75-80% and specificity of approximately 80% for diagnosing invasive candidiasis 6
• A positive result suggests the possibility of an invasive fungal infection but is not specific for any particular fungal pathogen 5
• False positive results are common, particularly in ICU patients, those on hemodialysis, and those receiving albumin or intravenous immunoglobulin infusions 7

Diagnostic Interpretation

• A positive Fungitell test should be considered as one component of a diagnostic workup, not as a standalone trigger for antifungal therapy 7
• The negative predictive value of the test is high, meaning a negative result can help rule out invasive fungal infection 8
• Multiple studies have shown that the positive predictive value is limited, particularly in ICU settings 9
• Consider potential causes of false positivity, including hemodialysis 10, administration of albumin or immunoglobulin products 10, and presence of certain medical materials 5

Treatment Decision Algorithm

• Assess clinical risk factors for invasive fungal infection, including presence of neutropenia 11, recent abdominal surgery with complications 12, and presence in ICU with multiple risk factors 10
• Obtain additional diagnostic tests, including blood cultures 11, site-specific cultures when applicable 10, and consider additional biomarkers (mannan/anti-mannan) if available 13
• Treatment initiation criteria include positive Fungitell PLUS clinical signs of infection PLUS high-risk factors 7, positive blood culture for Candida 10, and evidence of deep-seated candidiasis on imaging or biopsy 14

Antifungal Therapy Options

• For suspected invasive candidiasis in non-neutropenic patients, first-line treatment is Echinocandin (e.g., caspofungin) 11, and alternative treatment is Fluconazole 11
• For suspected invasive candidiasis in neutropenic patients, first-line treatment is Echinocandin or liposomal amphotericin B 11

Duration of Therapy

• For documented candidemia, treat for at least 14 days after the first negative blood culture and resolution of symptoms 11
• Perform ophthalmological examination to rule out endophthalmitis 11

Important Considerations

• Source control (e.g., removal of infected catheters, drainage of abscesses) is crucial for successful treatment 10
• Candida isolation from respiratory secretions should never trigger antifungal treatment, as this typically represents colonization rather than infection 10
• Remember that β-D-glucan can be positive in infections caused by Pneumocystis jirovecii and other fungi, not just Candida 5

Pitfalls to Avoid

• Do not rely solely on Fungitell results for treatment decisions 7
• Avoid unnecessary antifungal therapy based on colonization or single positive biomarker without supporting evidence 10

β‑D‑Glucan Testing: Indications, Interpretation, and Clinical Utility

Indications for Testing

• In patients with persistent fever and neutropenia despite ≥ 4 days of broad‑spectrum antibiotics, serum β‑D‑glucan testing is recommended to evaluate for invasive fungal infection. 15
• In critically ill patients who have multiple risk factors (e.g., central venous catheter, broad‑spectrum antibiotics, parenteral nutrition, dialysis, recent surgery, pancreatitis) and a clinical suspicion of invasive fungal infection, β‑D‑glucan testing is appropriate. 15
• Routine screening of general intensive‑care populations is not advised because of poor specificity; this applies to both single‑center and multicenter contexts. [15][16]

Interpretation of Positive Results (> 80 pg/mL)

• A single positive β‑D‑glucan result suggests a probable invasive fungal infection but does not identify the specific fungal species. 15
• The assay detects cell wall components of Candida, Aspergillus, Pneumocystis jirovecii, and Fusarium species. 15
• Reported sensitivity is 75–80 % for invasive candidiasis and approximately 80 % for invasive aspergillosis. 15
• Overall specificity is around 80 %, but it is markedly lower in intensive‑care settings. [15][16]
• Known false‑positive contributors that must be excluded before initiating antifungal therapy include:
  
  • Recent exposure to β‑lactam antibiotics (e.g., piperacillin‑tazobactam, amoxicillin‑clavulanate, cefepime, ceftriaxone, carbapenems, ampicillin‑sulbactam).
  • Hemodialysis, especially with cellulose‑based membranes. 15
  • Administration of albumin or intravenous immunoglobulin. 15
• Obtaining a second β‑D‑glucan measurement within 3–5 days and demonstrating consecutive positive results raises specificity to > 96 %. 15

Interpretation of Negative Results (< 80 pg/mL)

• A negative β‑D‑glucan result provides a high negative predictive value (> 90 %) and can effectively exclude invasive fungal infection when clinical context is appropriate. 15
• The test’s sensitivity may be diminished in patients already receiving mold‑active antifungal prophylaxis or therapy. 15

Test Performance and Limitations

Monitoring Treatment Response

• Declining serum β‑D‑glucan concentrations over time have been associated with clinical response to antifungal therapy, supporting its use as a therapeutic monitoring tool. 15